Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4619
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$26.28
Last synced: 2026-10-16
Market Cap
$3.30B
Change (1 day)
-4.95%
Change (1 year)
75.79%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Dividend history for Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (stock symbol: AMLX) made a total of 3 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $1.02
Dividend yield (TTM) : 0
The sum of all dividends (adjusted for stock splits) is : $1.02
Dividend yield (TTM) : 0
Dividend payments for Amylyx Pharmaceuticals, Inc. (AMLX) from 2017 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
